share_log

Earnings Call Summary | Materialise(MTLS.US) Q1 2024 Earnings Conference

Earnings Call Summary | Materialise(MTLS.US) Q1 2024 Earnings Conference

财报电话会议摘要 | Materialise (MTLS.US) 2024 年第一季度财报会议
moomoo AI ·  04/25 18:38  · 电话会议

The following is a summary of the Materialise NV (MTLS) Q1 2024 Earnings Call Transcript:

以下是Materialise NV(MTLS)2024年第一季度财报电话会议记录的摘要:

Financial Performance:

财务业绩:

  • Materialise NV's total Q1 2024 revenue slightly decreased by 3.4% to €63.6 million due to weak prototyping demand and the shift to cloud and subscription-based business model in the Software segment.

  • Gross margin, however, increased to 56.5% from 55.9% in the same period the previous year.

  • Adjusted EBIT amounted to €2.7 million, representing 4.2% of revenue while net profit was stable at €3.6 million or €0.06 per share.

  • The company's net cash position at the end of Q1 2024 was €69.2 million, an increase of €6 million from the start of the quarter.

  • 由于原型设计需求疲软以及软件领域转向基于云和订阅的业务模式,Materialise NV 2024年第一季度的总收入略有下降3.4%,至6,360万欧元。

  • 但是,毛利率从去年同期的55.9%增加到56.5%。

  • 调整后的息税前利润为270万欧元,占收入的4.2%,净利润稳定在360万欧元或每股0.06欧元。

  • 截至2024年第一季度末,该公司的净现金状况为6,920万欧元,比本季度初增加了600万欧元。

Business Progress:

业务进展:

  • Materialise NV made significant progress on its strategic priorities, launching new technologies, and extending its reach into new markets and segments.

  • Growth was seen in the market adoption of personalized medical cases and developments were made in new software solutions.

  • The move from prototyping to larger certified manufacturing projects is underway and they entered the trauma market with short lead times in the U.S. - expected to be a key growth driver.

  • They are focusing on untapped markets and investing in developing offerings for end-use product manufacturing, especially in software units. In addition, their investment in the CO-AM platform, which helps customers scale in the production of end-use products, continues to grow.

  • Materialise NV在战略优先事项、推出新技术以及将其业务范围扩展到新市场和细分市场方面取得了重大进展。

  • 个性化医疗案例的市场采用率有所增长,新的软件解决方案也有所发展。

  • 从原型设计向更大的认证制造项目的转变正在进行中,它们进入创伤市场时在美国的交货时间很短,预计这将是关键的增长动力。

  • 他们专注于未开发的市场,并投资开发最终用途产品制造产品,尤其是软件部门。此外,他们对CO-AM平台的投资持续增长,该平台可帮助客户扩大最终用途产品的生产。

More details: Materialise IR

更多详情: 实现红外线

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发